Oxytocin + Alk5 Inhibitor Combo Boosts Lifespan 70% in Elderly Mice: What the Science Actually Shows

A study from UC Berkeley, published in Aging-US in 2025, has generated significant attention for reporting a 73% life extension in frail, elderly male mice treated with a two-drug combination: oxytocin (OT) and an Alk5 inhibitor (A5i). Led by Cameron Kato and corresponding author Irina M. Conboy, the research represents a notable data point in the ongoing effort to pharmacologically reverse aspects of aging — but the details, especially the stark sex differences, deserve careful examination.

What the Researchers Did

The team started from a well-established premise: aging involves two major shifts in signaling pathways.

First, oxytocin declines with age. This hormone, sometimes called the “bonding hormone,” plays a broader role in tissue maintenance and repair. Its circulating levels drop as organisms get older, reducing regenerative capacity.

Second, TGF-beta signaling increases with age. The transforming growth factor-beta pathway, mediated in part through the ALK5 receptor, becomes overactive in older tissues. This drives inflammation, fibrosis, and what the authors describe as “biological noise” — dysregulated protein expression patterns that are themselves a hallmark of aging.

The dual strategy was straightforward: restore what declines (oxytocin) and suppress what becomes excessive (TGF-beta via Alk5 inhibition).

The researchers treated frail mice at 25 months of age — roughly equivalent to 75 human years — with regular OT+A5i injections and tracked them longitudinally.

The Results: 70%+ Lifespan Extension in Males

The headline finding is striking. Male mice treated with OT+A5i lived more than 70% longer than untreated controls from the point treatment began. The overall median lifespan increased by 14%. Hazard ratio analysis showed treated males were nearly three times less likely to die at any given moment compared to untreated mice.

Beyond raw survival, the treated males showed measurable improvements in:

• Agility and endurance — physical performance metrics improved markedly
• Memory — cognitive testing showed gains consistent with younger animals
• Systemic protein balance — circulating blood proteins adopted more “youthful” expression patterns, with reduced biological noise

The authors summarize: “Treatment of old frail male mice with OT+A5i resulted in a remarkable 73% life extension from that time, and a 14% increase in the overall median lifespan.”

The Critical Caveat: Female Mice Didn’t Benefit Long-Term

This is where the study becomes particularly important for anyone considering translational implications. Female mice showed no significant lifespan extension or sustained health improvements.

Both sexes experienced short-term gains, but after four months of continuous therapy, only males maintained the improvements in systemic protein balance. The researchers also noted that middle-aged females treated with the combo showed increased fertility — an interesting biological signal, but not the longevity outcome the study was designed to measure.

These findings, the authors write, “establish the significant health-span extension capacity of OT+A5i and emphasize the differences in aging and in response to longevity therapeutics between the sexes.”

This is not a minor footnote. Sex-specific responses to aging interventions are one of the most underappreciated variables in longevity research. Drugs that show dramatic effects in one sex may be ineffective — or even counterproductive — in the other. The TGF-beta pathway is known to interact with estrogen signaling, which may partially explain the divergence, though the precise mechanisms remain under investigation.

How This Fits Into the Broader Landscape

The OT+A5i approach aligns with a growing body of research targeting signaling pathway modulation rather than single-disease treatment. Several converging lines of evidence support this direction:

• Rapamycin, the most-studied pharmacological longevity intervention, also works partly through TGF-beta pathway modulation and has shown sex-specific dosing requirements in mice (UT Health San Antonio rapamycin trial coverage)
• Senolytics aim to clear damaged cells that drive TGF-beta overactivation, though clinical translation has been slower than hoped (senolytics clinical trial review)
• NAD+ precursors target a different axis of age-related decline — mitochondrial dysfunction — but share the goal of restoring youthful signaling patterns (NAD+ therapy evidence guide)

The Conboy lab’s contribution is notable for using already-frail, elderly animals rather than starting treatment in middle age. Most longevity studies begin interventions in relatively young animals, which limits their relevance to the populations most likely to seek treatment.

Could This Work in Humans?

The honest answer: nobody knows, and anyone who tells you otherwise is speculating.

Here’s what we can say with confidence:

1. Oxytocin is FDA-approved — for labor induction in obstetrics. It has a known safety profile at acute doses. Chronic administration at anti-aging doses has not been studied in humans.

2. Alk5 inhibitors are in clinical trials — but for cancer and fibrotic diseases, not longevity. Several pharmaceutical companies are developing ALK5-targeting compounds, which could accelerate the path to testing the combination.

3. Mouse-to-human translation is unreliable — the field is littered with interventions that produced dramatic lifespan extensions in mice (rapamycin, metformin, acarbose, 17-alpha-estradiol) but have yet to demonstrate comparable effects in humans. The 70% figure, while real in this mouse cohort, should be understood in that context.

4. The sex-specific results are a red flag for broad clinical application — any human trial would need to carefully stratify by sex and consider whether the biological basis for the male-specific benefit even exists in humans.

What Longevity Clinics Are Doing With This Information

Some longevity clinics already offer oxytocin as part of peptide therapy protocols. This study will likely increase that trend. Patients should be aware:

• No clinic is offering the specific OT+A5i combination tested in this study. Alk5 inhibitors are not commercially available as longevity drugs.
• Oxytocin alone is not the intervention. The study’s effect depended on the combination, not oxytocin by itself.
• The evidence base for oxytocin as a longevity peptide in humans is essentially zero. Clinics offering it are extrapolating from animal data.

For a broader view of what evidence-based clinics actually offer, see our comprehensive guide to the best longevity clinics in 2026.

The Bottom Line

The Conboy lab’s study is legitimately interesting science. It demonstrates that a simple two-drug combination, started late in life, can dramatically extend both lifespan and healthspan in a mouse model — at least in males. The sex-specific findings are scientifically important and underscore how much we still don’t understand about the biology of aging.

But this is a single study in a single strain of mice. The path from these results to a human therapy runs through years of additional research: dose-finding studies, safety profiling of chronic Alk5 inhibition, sex-stratified efficacy trials, and eventually large-scale human longevity trials that don’t yet exist.

The researchers deserve credit for pushing the field forward. The rest of us should resist the temptation to skip several steps.

Other Clinics Worth Considering

If you’re exploring evidence-based longevity programs, these clinics combine research-grade diagnostics with transparent, science-forward approaches:

• Lanserhof — Austrian luxury longevity clinic with LANS Med concept integrating modern medicine with traditional healing
• SHA Wellness Clinic — Spanish clinic offering genetic testing, advanced diagnostics, and integrated wellness programs
• Clinique La Prairie — Swiss clinic with six-decade track record in longevity and revitalization
• Human Longevity Inc. — Genomics-focused health assessment using whole-genome sequencing and advanced imaging

---

Sources:

• Kato C, Conboy IM et al. “Sex-specific longitudinal reversal of aging in old frail mice.” Aging-US, 2025. PubMed PMID: 40848270
• ScienceDaily. “Scientists boost lifespan by 70% in elderly male mice using simple drug combo.” December 2025. Link
• Aging-US News Room. “Sex-Specific Effects Found in New Anti-Aging Therapy for Elderly Mice.” October 2025. Link